6,000 Shares in Veeva Systems Inc. $VEEV Bought by Vilga Financial Planning LLC

Vilga Financial Planning LLC bought a new position in shares of Veeva Systems Inc. (NYSE:VEEV) in the third quarter, Holdings Channel reports. The firm bought 6,000 shares of the technology company’s stock, valued at approximately $1,713,000. Veeva Systems accounts for 1.0% of Vilga Financial Planning LLC’s portfolio, making the stock its 25th largest position.

A number of other institutional investors and hedge funds have also modified their holdings of the company. SHP Wealth Management acquired a new position in Veeva Systems in the 4th quarter valued at $26,000. Compass Financial Management LLC acquired a new stake in shares of Veeva Systems in the second quarter valued at about $27,000. Burkett Financial Services LLC bought a new position in shares of Veeva Systems in the third quarter worth about $27,000. Arlington Trust Co LLC acquired a new position in shares of Veeva Systems during the 2nd quarter worth about $29,000. Finally, Field & Main Bank acquired a new position in shares of Veeva Systems during the 2nd quarter worth about $29,000. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on VEEV. Robert W. Baird lifted their price target on Veeva Systems from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th. Stifel Nicolaus set a $300.00 target price on shares of Veeva Systems in a research note on Thursday, August 27th. Barclays increased their price target on shares of Veeva Systems from $275.00 to $315.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Piper Sandler raised their price target on shares of Veeva Systems from $295.00 to $320.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. Finally, Morgan Stanley upped their price objective on shares of Veeva Systems from $215.00 to $275.00 and gave the company an “equal weight” rating in a research report on Thursday, August 27th. Nineteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $284.88.

Veeva Systems News Summary

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva Basics adoption is accelerating. More than 175 emerging biotechs have standardized on Veeva Basics, which offers preconfigured applications spanning clinical, regulatory, quality, medical, and commercial operations. The customer count supports Veeva’s strategy of landing smaller biotech companies early and expanding with them as they grow. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical data automation is scaling. Veeva’s Development Quality Suite has processed data for more than 1 million clinical-trial subjects across over 1,000 studies. The adoption demonstrates expanding use of Veeva’s software in critical research workflows and reinforces the company’s data and switching-cost advantages. Veeva’s DQS Scales Data Automation Across 1,000+ Clinical Studies
• Positive Sentiment: AI and industry visibility are supporting the investment case. Veeva’s upcoming R&D and Quality Summit will feature major customers including Eli Lilly, Pfizer, Sanofi, and UCB, highlighting AI innovations and more efficient drug development. Separately, technical coverage says VEEV is approaching potential buy points after nearly doubling, suggesting renewed institutional interest and strong momentum. Veeva Summit to Showcase AI Innovations
• Neutral Sentiment: Valuation and momentum warrant caution. Analysts describe Veeva as a sticky, mission-critical platform for pharmaceutical customers, but the stock has already rebounded substantially and is trading near its yearly high. Further gains may depend on evidence that AI features, customer additions, and expansion are translating into faster revenue and earnings growth.
• Negative Sentiment: Insider selling and mixed commentary are potential headwinds. Insider Daniel Rizzo sold 4,841 shares, while Jim Cramer expressed a preference for Salesforce over Veeva among software recovery plays. These developments do not change the operating outlook but could encourage profit-taking after the recent advance. Veeva Systems Insider Share Sale

Veeva Systems Stock Performance

Shares of Veeva Systems stock opened at $284.78 on Friday. The firm has a market cap of $46.11 billion, a P/E ratio of 46.84, a price-to-earnings-growth ratio of 1.21 and a beta of 0.93. The firm’s 50-day simple moving average is $259.17 and its 200-day simple moving average is $202.93. Veeva Systems Inc. has a twelve month low of $148.05 and a twelve month high of $303.39.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.23 by $0.12. The firm had revenue of $927.96 million during the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.99 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, equities analysts forecast that Veeva Systems Inc. will post 6.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Daniel Rizzo sold 4,841 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $276.51, for a total value of $1,338,584.91. Following the sale, the executive vice president owned 7,665 shares of the company’s stock, valued at $2,119,449.15. The trade was a 38.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Thomas Schwenger sold 36,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $250.23, for a total value of $9,008,280.00. Following the transaction, the insider owned 19,449 shares of the company’s stock, valued at $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,591 shares of company stock worth $13,355,945 in the last 90 days. 10.60% of the stock is owned by company insiders.

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.